Cannell & Co. Biodesix Inc Transaction History
Cannell & Co.
- $3.01 Billion
- Q4 2023
A detailed history of Cannell & Co. transactions in Biodesix Inc stock. As of the latest transaction made, Cannell & Co. holds 205,605 shares of BDSX stock, worth $351,584. This represents 0.01% of its overall portfolio holdings.
Number of Shares
205,605
Previous 205,605
-0.0%
Holding current value
$351,584
Previous $339,000
11.5%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding BDSX
# of Institutions
51Shares Held
53.6MCall Options Held
500Put Options Held
11.5K-
Telemark Asset Management, LLC Boston, MA8.28MShares$14.2 Million1.22% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.11MShares$10.5 Million0.95% of portfolio
-
Aigh Capital Management LLC Baltimore, MD5.78MShares$9.88 Million3.2% of portfolio
-
Birchview Capital, LP Burlington, VT5.54MShares$9.48 Million8.47% of portfolio
-
Sio Capital Management, LLC New York, NY4.35MShares$7.43 Million2.48% of portfolio
About BIODESIX INC
- Ticker BDSX
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 39,982,000
- Market Cap $68.4M
- Description
- Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pat...